ClinicalTrials.gg
RecruitingNCT07021898BOREALIS-1Updated Dec 3, 2025

A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.

A Phase 1 interventional study of ERAS-4001 and ERAS-4001 in combination in Metastatic Solid Tumors, sponsored by Erasca, Inc.. Recruiting at 5 sites in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2025-12-03.

Sponsored by Erasca, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
200
Allocation
Non-randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 2,056 studies in Neoplasm Metastasis with a site in United States — 346 open to participants now, 543 under way, 58 of them phase 3. Neoplasm Metastasis · United States.

Planned enrollment
301st of 1,865
200 · median 43
Started
2025
with 84 others
Phase 1
710 of 2,056
128 open now
Primary completion
2028-08
later than 409 of 541 live
Registered
1,947th of 2,056
by date

Among the 2,056 studies in Neoplasm Metastasis with a site in United States, this one is the 301st largest by planned enrollment of the 1,865 interventional ones that give a count, is one of 85 that started in 2025, is one of 710 in phase 1, reaches primary completion later than 409 of the 541 other live ones, and was the 1,947th registered.

Neoplasm Metastasis

4,051 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

346 of the 2,056 studies in Neoplasm Metastasis with a site in United States are open now. Recruiting first, the newest first:

341 more — sign in →

All 346 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 691 Neoplasm Metastasis studies recruiting now, 538 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,056 studies in Neoplasm Metastasis with a site in United States, or all of them as a file.
02

Study summary

The main purpose of the study is to assess whether the study drug, ERAS-4001, is safe and tolerable when administered to patients with advanced or metastatic solid tumors with certain KRAS mutations. ERAS-4001 will be given alone or in combination with other treatments.

Read the detailed description

This is a first-in-human, Phase 1/1b, open-label, multicenter clinical study of ERAS-4001 as a monotherapy and in combination with other cancer therapies. The study will commence with dose optimization of ERAS-4001 monotherapy, followed by dose optimization of ERAS-4001 in combination with other cancer therapies.

03

Conditions studied

  • Metastatic Solid Tumors

Keywords

  • Solid Tumor
  • Advanced Solid Tumor
  • Solid malignancies
  • Targeted therapy
  • Molecular alterations
  • pembrolizumab
  • Keytruda
  • panitumumab
  • Vectibix
  • Metastatic solid tumor
  • Neoplasms
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Willing and able to give written
  • Pathological documentation of tumor type and mutation prior to the first dose of study drug(s)
  • There is no available standard systemic therapy available for the patient's tumor histology and/or molecular biomarker profile; or standard therapy is intolerable, not effective, or not accessible; or patient has refused standard therapy
  • Able to swallow oral medication
  • Have Performance Status (ECOG PS) of 0 or 1
  • Adequate cardiovascular, hematological, liver, and renal function
  • Willing to comply with all protocol-required visits, assessments, and procedures

Exclusion criteria

Exclusion Criteria:

  • Previous treatment with a RAS inhibitor
  • Is currently receiving another study therapy or has participated in a study of an agent and received study therapy within 4 weeks of the first dose of ERAS-4001
  • Received prior palliative radiation within 14 days of Cycle 1, Day 1
  • Have primary central nervous system (CNS) tumors
  • Prior surgery (e.g., gastric bypass surgery, gastrectomy) or gastrointestinal dysfunction (e.g., Crohn's disease, ulcerative colitis, short gut syndrome) that may affect drug absorption
  • Have any underlying medical condition, psychiatric condition, or social situation that, in the opinion of the Investigator, would compromise study administration as per protocol or compromise the assessment of AEs
  • Are pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    ERAS-4001 Monotherapy Dose Optimization.

    Escalating doses of ERAS-4001 administered orally.

    Drug: ERAS-4001

  • Experimental
    ERAS-4001 Combination Dose Optimization

    ERAS-4001 administered orally with another investigational agent.

    Drug: ERAS-4001 in combination

Interventions

  • DrugERAS-4001

    ERAS-4001 Administered orally

  • DrugERAS-4001 in combination

    ERAS-4001 Administered orally and in combination with either Keytruda (pembrolizumab) via IV administration or Vectibix (panitumumab) via IV administration.

    Also known as: Keytruda (pembrolizumab), Vectibix (panitumumab)

This study also gives Pembrolizumab. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Dose Limiting Toxicities (DLT)

    Based on toxicities observed

    Time frame: Study Day 1 up to Day 21

  2. Maximum tolerated dose (MTD)

    Based on toxicities observed

    Time frame: Study Day 1 up to Day 21

  3. Recommended dose for expansion (RDE)

    Based on toxicities observed

    Time frame: Study Day 1 up to Day 21

  4. Adverse Events

    Incidence and severity of treatment-emergent AEs and serious AEs

    Time frame: Study Day 1 up to Day 21

  5. Plasma concentration (Cmax)

    Maximum plasma concentration of ERAS-4001

    Time frame: Study Day 1 up to Day 65

  6. Time to achieve Cmax (Tmax)

    Time of achieve maximum plasma concentration of ERAS-4001

    Time frame: Study Day 1 up to Day 65

  7. Area under the curve

    Area under the plasma concentration-time curve of ERAS-4001

    Time frame: Study Day 1 up to Day 65

  8. Half-life

    Half-life of ERAS-4001

    Time frame: Study Day 1 up to Day 65

Secondary outcomes

  1. Objective Response Rate (ORR)

    Based on assessment of radiographic imaging per RECIST version 1.1

    Time frame: Assessed up to 24 months from time of first dose

  2. Duration of Response (DOR)

    Based on assessment of radiographic imaging per RECIST version 1.1

    Time frame: Assessed up to 24 months from time of first dose

  3. Time to Response (TTR)

    Based on assessment of radiographic imaging per RECIST version 1.1

    Time frame: Assessed up to 24 months from time of first dose

07

Study locations

5 of 5 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Aug 2028, 36 months after the start.

Of 288 industry-sponsored phase 1 interventional studies under Neoplasm Metastasis, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 75. This study's planned 36 months is below that.

Counting every sponsor, half of 498 studies reached it within 54 months; a quarter within 33 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2025
First posted
Jun 15, 2025
StartActual
Aug 6, 2025
Primary completionEst.
Aug 2028
CompletionEst.
Dec 2028
Last update
Dec 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07021898
Lead sponsor
Erasca, Inc.
Responsible party
Sponsor
First posted
Jun 15, 2025
Start date
Aug 6, 2025
Primary completion
Aug 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Dec 3, 2025

Study contacts

Erasca Clinical Team
Contact
clinicaltrials@erasca.com
+1-858-465-6511
Les Brail, Study Director, PhD
Contact
Gerri Lee
study director · Erasca, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion